Skip to main content
. Author manuscript; available in PMC: 2020 Aug 12.
Published in final edited form as: Ann Otol Rhinol Laryngol. 2014 Aug 13;124(2):110–115. doi: 10.1177/0003489414546400

Figure 3.

Figure 3.

Xenograft growth kinetics. Two xenografts derived from the previous generation (P2) were grafted into 2 mice simultaneously (P3). Once the tumor was palpable (week 6), treatment began with intraperitoneal bevacizumab (5 mg/kg) or saline control. Tumor growth was measured with calipers weekly. The bevacizumab-treated xenograft showed dramatic tumor regression compared to saline control.